Patent · US Active

Sustained drug delivery implant

US9610246B2 · kind B2 · utility

4Cited by

138References

3Claims

0Family size

Assignee

Allergan, Inc. · US

Inventors

Jane-Guo Shiah · Irvine, US
Chetan P. Pujara · Irvine, US

Key dates

Filing date	Mar 18, 2014
Grant date	Apr 4, 2017
Priority date	—
Expiry date	Mar 18, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61F2210/0004
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.